{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:51:30Z","timestamp":1792075890153,"version":"4.4.0"},"reference-count":110,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T00:00:00Z","timestamp":1693094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Endometrial cancer (EC) stands as the most prevalent gynecologic malignancy. In the past, it was classified based on its hormone sensitivity. However, The Cancer Genome Atlas has categorized EC into four groups, which offers a more objective and reproducible classification and has been shown to have prognostic and therapeutic implications. Hormonally driven EC arises from a precursor lesion known as endometrial hyperplasia, resulting from unopposed estrogen. EC is usually diagnosed through biopsy, followed by surgical staging unless advanced disease is expected. The typical staging consists of a hysterectomy with bilateral salpingo-oophorectomy and sentinel lymph node biopsies, with a preference placed on a minimally invasive approach. The stage of the disease is the most significant prognostic marker. However, factors such as age, histology, grade, myometrial invasion, lymphovascular space invasion, tumor size, peritoneal cytology, hormone receptor status, ploidy and markers, body mass index, and the therapy received all contribute to the prognosis. Treatment is tailored based on the stage and the risk of recurrence. Radiotherapy is primarily used in the early stages, and chemotherapy can be added if high-grade histology or advanced-stage disease is present. The risk of EC recurrence increases with advances in stage. Among the recurrences, vaginal cases exhibit the most favorable response to treatment, typically for radiotherapy. Conversely, the treatment of widespread recurrence is currently palliative and is best managed with chemotherapy or hormonal agents. Most recently, immunotherapy has emerged as a promising treatment for advanced and recurrent EC.<\/jats:p>","DOI":"10.3390\/curroncol30090574","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T06:57:35Z","timestamp":1693205855000},"page":"7904-7919","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["An Overview of Endometrial Cancer with Novel Therapeutic Strategies"],"prefix":"10.3390","volume":"30","author":[{"given":"Theresa M.","family":"Kuhn","sequence":"first","affiliation":[{"name":"Gynecologic Oncology Program, AdventHealth Cancer Institute, Orlando, FL 32804, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeeda","family":"Dhanani","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Program, AdventHealth Cancer Institute, Orlando, FL 32804, USA"},{"name":"Philadelphia College of Osteopathic Medicine, Suwanee, GA 30024, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5180-0409","authenticated-orcid":false,"given":"Sarfraz","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Program, AdventHealth Cancer Institute, Orlando, FL 32804, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/biolre\/ioaa183","article-title":"In vitro models of the human endometrium: Evolution and application for women\u2019s health","volume":"104","author":"Fitzgerald","year":"2021","journal-title":"Biol. Reprod."},{"key":"ref_2","unstructured":"Creasman, W.T., Mutch, D.G., Mannel, R.S., and Tewari, K.S. (2022). DiSaia and Creasman Clinical Gynecology Oncology, Elsevier. [10th ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","article-title":"Endometrial cancer","volume":"399","author":"Crosbie","year":"2022","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Santoro, A., Angelico, G., Travaglino, A., Inzani, F., Arciuolo, D., Valente, M., D\u2019Alessandris, N., Scaglione, G., Fiorentino, V., and Raffone, A. (2021). New pathological and clinical insights in endometrial cancer in view of the updated ESGO\/ESTRO\/ESP Guidelines. Cancers, 13.","DOI":"10.3390\/cancers13112623"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Levine","year":"2013","journal-title":"Nature"},{"key":"ref_8","first-page":"189","article-title":"The cytodynamics of endometrial hyperplasia and carcinoma: A review","volume":"3","author":"Ferenczy","year":"1983","journal-title":"Ann. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/1097-0142(19850715)56:2<403::AID-CNCR2820560233>3.0.CO;2-X","article-title":"The behavior of endometrial hyperplasia: A long-term study of \u201cuntreated\u201d hyperplasia in 170 patients","volume":"56","author":"Kurman","year":"1985","journal-title":"Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.5114\/pm.2017.70589","article-title":"New classification system of endometrial hyperplasia WHO 2014 and its clinical implications","volume":"16","author":"Sobczuk","year":"2017","journal-title":"Menopause Rev.\/Przegl\u0105d Menopauzalny"},{"key":"ref_11","unstructured":"Ellenson, L.H., Matias-Guiu, X., and Mutter, G.L. (2020). WHO Classification of Tumours Editorial Board\u2014Female Genital Tumours, WHO. [5th ed.]. WHO Classification of Tumours Series."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1097\/PAS.0000000000001705","article-title":"Atypical endometrial hyperplasia, low-grade","volume":"45","author":"Espinosa","year":"2021","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/cncr.21650","article-title":"Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: A GOG study","volume":"106","author":"Trimble","year":"2006","journal-title":"Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1097\/IGC.0b013e31826302a3","article-title":"Predicting the coexistence of an endometrial adenocarcinoma in the presence of atypical complex hyperplasia: Immunohistochemical analysis of endometrial samples","volume":"22","author":"Robbe","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ygyno.2014.10.008","article-title":"Clinically significant endometrial cancer risk following a diagnosis of complex atypical hyperplasia","volume":"135","author":"Costales","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1479-828X.2009.00981.x","article-title":"The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia: An Australian study and systematic review","volume":"49","author":"Buttini","year":"2009","journal-title":"Aust. N. Z. J. Obstet. Gynaecol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ygyno.2022.10.023","article-title":"Is sentinel lymph node assessment useful in patients with a preoperative diagnosis of endometrial intraepithelial neoplasia?","volume":"168","author":"Matanes","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2022.10.017","article-title":"Sentinel lymph node mapping in patients with endometrial hyperplasia: A practice to preserve or abandon?","volume":"168","author":"Mueller","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.3802\/jgo.2016.27.e8","article-title":"Therapeutic options for management of endometrial hyperplasia","volume":"27","author":"Chandra","year":"2016","journal-title":"J. Gynecol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.3802\/jgo.2017.28.e1","article-title":"Dilatation and curettage is more accurate than endometrial aspiration biopsy in early-stage endometrial cancer patients treated with high dose oral progestin and levonorgestrel intrauterine system","volume":"28","author":"Kim","year":"2017","journal-title":"J. Gynecol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/AOG.0b013e31820205b3","article-title":"Lifestyle challenges in endometrial cancer survivorship","volume":"117","author":"Waggoner","year":"2011","journal-title":"Obstet. Gynecol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/S0020-7292(06)60031-3","article-title":"Carcinoma of the corpus uteri","volume":"95","author":"Creasman","year":"2006","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1097\/IGC.0000000000001076","article-title":"Clinical utility of preoperative computed tomography in patients with endometrial cancer","volume":"27","author":"Bogani","year":"2017","journal-title":"Int. J. Gynecol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1067\/mob.2003.304","article-title":"CA125 levels in the preoperative assessment of advanced stage uterine cancer","volume":"188","author":"Jhang","year":"2003","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/(SICI)1097-0142(19960315)77:6<1115::AID-CNCR17>3.0.CO;2-4","article-title":"Pathologic models to predict outcome for women with endometrial adenocarcinoma","volume":"77","author":"Zaino","year":"1996","journal-title":"Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/01.AOG.0000255980.88205.15","article-title":"Prognostic factors for uterine cancer in reproductive-aged women","volume":"109","author":"Lee","year":"2007","journal-title":"Obstet. Gynecol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/0046-8177(95)90204-X","article-title":"p53 in endometrial carcinoma and its putative precursors: Evidence for diverse pathways for tumorigenesis","volume":"26","author":"Sherman","year":"1995","journal-title":"Hum. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1006\/gyno.1998.5147","article-title":"Papillary serous and clear cell carcinoma limited to endometrial curettings in FIGO stage Ia and Ib endometrial adenocarcinoma: Treatment implications","volume":"71","author":"Lim","year":"1998","journal-title":"Gynecol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO;2-8","article-title":"Surgical pathologic spread patterns of endometrial cancer","volume":"60","author":"Creasman","year":"1987","journal-title":"Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1002\/1097-0142(19850415)55:8<1753::AID-CNCR2820550823>3.0.CO;2-P","article-title":"The prognostic significance of lymph-vascular space invasion in stage I endometrial cancer","volume":"55","author":"Hanson","year":"1985","journal-title":"Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.ejca.2015.05.015","article-title":"Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer: A pooled analysis of PORTEC 1 and PORTEC 2 trials","volume":"51","author":"Bosse","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ygyno.2013.10.023","article-title":"High-grade endometrial cancer: Revisiting the impact of tumor size and location on outcomes","volume":"132","author":"Doll","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ygyno.2013.06.037","article-title":"Risk-scoring system for individualized prediction of lymphatic dissemination in patients with endometrioid endometrial cancer","volume":"131","author":"Podratz","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0090-8258(91)90086-K","article-title":"Relationship between surgical-pathologic risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A Gynecologic Oncology Group study","volume":"40","author":"Morrow","year":"1991","journal-title":"Gynecol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1525-1438.1992.02050225.x","article-title":"The clinical significance of malignant peritoneal cytology in stage I endometrial carcinoma","volume":"2","author":"Milosevic","year":"1992","journal-title":"Int. J. Gynecol. Cancer."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1006\/gyno.2001.6301","article-title":"Positive peritoneal cytology in endometrial cancer: Enhancement of other prognostic indicators","volume":"82","author":"Takeshima","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/1097-0142(19830501)51:9<1705::AID-CNCR2820510924>3.0.CO;2-C","article-title":"Carcinoma of the endometrium: An analysis of prognosticators in patients with favorable subtypes and stage I disease","volume":"51","author":"Christopherson","year":"1983","journal-title":"Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/00004347-199810000-00004","article-title":"DNA content is an independent prognostic indicator in endometrial adenocarcinoma","volume":"17","author":"Zaino","year":"1998","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1525-1438.2007.00845.x","article-title":"The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: A prospective immunocytochemical study","volume":"17","author":"Athanassiadou","year":"2007","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"890908","DOI":"10.3389\/fonc.2022.890908","article-title":"Current and emerging prognostic biomarkers in endometrial cancer","volume":"12","author":"Njoku","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Alexa, M., Hasenburg, A., and Battista, M.J. (2021). The TCGA molecular classification of endometrial cancer and its possible impact on adjuvant treatment decisions. Cancers, 13.","DOI":"10.3390\/cancers13061478"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ygyno.2015.10.020","article-title":"Body mass index and mortality in endometrial cancer: A systematic review and meta-analysis","volume":"140","author":"Secord","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/0360-3016(85)90272-X","article-title":"Stage II carcinoma of the endometrium: Results of therapy and prognostic factors","volume":"11","author":"Grigsby","year":"1985","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/jama.2017.2068","article-title":"Effect of total laparoscopic hysterectomy vs total abdominal hysterectomy on disease-free survival among women with stage I endometrial cancer. A randomized clinical trial","volume":"317","author":"Janda","year":"2017","journal-title":"JAMA"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/AOG.0000000000002428","article-title":"Adoption of minimally invasive surgery decrease in surgical morbidity for endometrial cancer treatment in the United States","volume":"131","author":"Casarin","year":"2018","journal-title":"Obstet. Gynecol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ygyno.2017.05.027","article-title":"Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations","volume":"146","author":"Holloway","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1245\/s10434-017-5825-3","article-title":"A prospective cohort study comparing colorimetric and fluorescent imaging for sentinel lymph node mapping in endometrial cancer","volume":"24","author":"Holloway","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S1470-2045(17)30068-2","article-title":"A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): A multicentre, prospective, cohort study","volume":"18","author":"Rossi","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_49","first-page":"1180","article-title":"Intraoperative frozen section assessment of myometrial invasion and histology of endometrial cancer using the revised FIGO staging system","volume":"21","author":"Ugaki","year":"2011","journal-title":"Int. J. Gynecol. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ygyno.2014.03.569","article-title":"Intra-operative frozen section results reliably predict final pathology in endometrial cancer","volume":"133","author":"Stephan","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/AOG.0b013e318240de51","article-title":"Nodal metastasis risk in endometrioid endometrial cancer","volume":"119","author":"Milam","year":"2012","journal-title":"Obstet. Gynecol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ygyno.2011.02.037","article-title":"The significance of surgical staging in intermediate-risk endometrial cancer","volume":"122","author":"Kwon","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ygyno.2006.01.032","article-title":"Efficacy of systematic lymphadenectomy and adjuvant radiotherapy in node-positive endometrial cancer patients","volume":"10","author":"Mariani","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ygyno.2013.10.002","article-title":"Prospective assessment of the prevalence of pelvic, paraaortic and high paraaortic lymph node metastasis in endometrial cancer","volume":"132","author":"Kumar","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ygyno.2015.09.001","article-title":"Canadian high-risk endometrial cancer (CHREC) consortium: Analyzing the clinical behavior of high-risk endometrial cancers","volume":"139","author":"Altman","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/S0140-6736(00)02139-5","article-title":"Surgery and postoperative radiotherapy versus surgery alone for patients with stage I endometrial carcinoma: A multicenter randomized trial, Post Operative Radiation Therapy in Endometrial Carcinoma (PORTEC) Study Group","volume":"355","author":"Creutzberg","year":"2000","journal-title":"Lancet"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1046\/j.1525-1438.1996.06010038.x","article-title":"Adjuvant radiation therapy is not necessary in the management of endometrial carcinoma stage I, low-risk cases","volume":"6","author":"Poulsen","year":"1996","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/IGC.0b013e3181a6c9df","article-title":"Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: A controlled randomized study","volume":"19","author":"Sorbe","year":"2009","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(09)62163-2","article-title":"Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): An open-label, non-inferiority, randomized trial","volume":"375","author":"Nout","year":"2010","journal-title":"Lancet"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1471-0528.2007.01332.x","article-title":"Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: Systematic review and meta-analysis","volume":"114","author":"Johnson","year":"2007","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): Final results of an international, open-label, multicentre, randomized, phase 3 trial","volume":"19","author":"Powell","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1200\/JCO.18.01575","article-title":"A phase III trial: Adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel\/carboplatin in high-intermediate and high-risk early-stage endometrial cancer","volume":"37","author":"Randall","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ygyno.2017.04.006","article-title":"Nonoperative management of atypical endometrial hyperplasia and grade I endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women","volume":"146","author":"Baker","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ygyno.2018.03.002","article-title":"The role of adjuvant therapy in stage IA serous and clear cell uterine cancer: A multi-institutional pooled analysis","volume":"149","author":"Qu","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ygyno.2015.09.064","article-title":"Patterns of care, associations, and outcomes of chemotherapy for uterine serous carcinoma: Analysis of the National Cancer Database","volume":"139","author":"Diver","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/IGC.0000000000000856","article-title":"Comparison of survival benefits of combined chemotherapy and radiotherapy versus chemotherapy alone for uterine serous carcinoma: A meta-analysis","volume":"27","author":"Lin","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ygyno.2011.10.007","article-title":"Phase II trial of adjuvant pelvic radiation \u201csandwiched\u201d between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma","volume":"124","author":"Einstein","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ygyno.2006.10.013","article-title":"Endometrial cancer: Revisiting the importance of pelvic and paraaortic lymph nodes","volume":"104","author":"Aalders","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1006\/gyno.2000.5843","article-title":"Stage IVB endometrial carcinoma: The role of cytoreductive surgery and determinants of survival","volume":"78","author":"Bristow","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/ijgc-2021-002753","article-title":"Uterine serous carcinoma: Key advances and novel treatment approaches","volume":"31","author":"Ferriss","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_71","unstructured":"Berek, J., and Hacker, N. (2021). Gynecologic Oncology, Wolters Kluwer. [7th ed.]."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/ijgc-00009577-200301000-00006","article-title":"Simultaneous carcinoma of the endometrium and ovary vs endometrial carcinoma with ovarian metastases: A clinical and immunohistochemical determination","volume":"13","author":"Habler","year":"2003","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_73","first-page":"741","article-title":"Endometrial adenocarcinoma in women under 25 years of age","volume":"68","author":"Farhi","year":"1986","journal-title":"Obstet. Gynecol."},{"key":"ref_74","unstructured":"Royal College of Obstetricians and Gynaecologists (2013). Fertility Sparing Treatments in Gynaecological Oncology, Royal College of Obstetricians and Gynaecologists. Scientific Impact Paper No. 35."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ygyno.2014.02.020","article-title":"Fertility sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin","volume":"133","author":"Simpson","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.ygyno.2004.10.031","article-title":"Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature","volume":"97","author":"Dhar","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/AOG.0000000000001647","article-title":"Ovarian conservation and overall survival in young women with early-stage low-grade endometrial cancer","volume":"128","author":"Matsuo","year":"2016","journal-title":"Obstet. Gynecol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/IGC.0000000000000895","article-title":"Impact of conservative managements in young women with grade 2 or 3 endometrial adenocarcinoma confined to the endometrium","volume":"27","author":"Gonthier","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/AOG.0b013e31827237ef","article-title":"Missed opportunities for primary endometrial cancer prevention: How to optimize early identification and treatment of high-risk women","volume":"120","author":"Modesitt","year":"2012","journal-title":"Obstet. Gynecol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/AOG.0b013e3181b11ecc","article-title":"Lynch syndrome screening strategies among newly diagnosed endometrial cancer patients","volume":"114","author":"Resnick","year":"2009","journal-title":"Obstet. Gynecol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0090-8258(84)90063-5","article-title":"Recurrent adenocarcinoma of the endometrium: A clinical and histopathological study of 379 patients","volume":"17","author":"Aalders","year":"1984","journal-title":"Gynecol. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"100922","DOI":"10.1016\/j.gore.2022.100922","article-title":"Disparities in cancer-specific and overall survival in black women with endometrial cancer: A Medicare-SEER study","volume":"40","author":"Saris","year":"2022","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"R\u00fctten, H., Verhoef, C., van Weelden, W.J., Smits, A., Dhanis, J., Ottevanger, N., and Pijnenborg, J.M.A. (2021). Recurrent endometrial cancer: Local and systemic treatment options. Cancers, 13.","DOI":"10.3390\/cancers13246275"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ygyno.2014.02.019","article-title":"Improving oncologic outcomes for women with endometrial cancer: Realigning our sights","volume":"133","author":"Dowdy","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and paclitaxel for advanced endometrial cancer: Final overall survival and adverse event analysis of a phase III trial (NRG Oncology\/GOG0209)","volume":"38","author":"Miller","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1200\/jco.2015.33.15_suppl.5502","article-title":"Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III-IV) or recurrent endometrial cancer: The MITO END-2 trial","volume":"33","author":"Lorusso","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/COC.0b013e31829a2974","article-title":"Advances in the management of recurrent endometrial cancer","volume":"38","author":"Bradford","year":"2015","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2015.07.096","article-title":"Management of nodal recurrences of endometrial cancer with IMRT","volume":"139","author":"Ho","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/j.1525-1438.2007.00858.x","article-title":"Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: A multi-institutional experience","volume":"17","author":"Huh","year":"2007","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S0360-3016(03)00414-0","article-title":"Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy","volume":"56","author":"Jhingran","year":"2003","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ygyno.2011.09.031","article-title":"Pelvic exenteration with curative intent for recurrent uterine malignancies","volume":"124","author":"Einstein","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ygyno.2006.03.011","article-title":"Salvage cytoreductive surgery for recurrent endometrial cancer","volume":"103","author":"Bristow","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1200\/JCO.1999.17.6.1736","article-title":"Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: A dose-response study by the Gynecologic Oncology Group","volume":"17","author":"Thigpen","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1200\/JCO.1991.9.6.1071","article-title":"Systemic treatment of advanced and recurrent endometrial cancer: Current status and future directions","volume":"9","author":"Moore","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.ajog.2008.04.012","article-title":"Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole","volume":"199","author":"Bellone","year":"2008","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1200\/JCO.2016.34.15_suppl.5520","article-title":"Phase II study of anastrozole in recurrent estrogen (ER)\/progesterone (PR) positive endometrial cancer: The PARAGON trial\u2013ANZGOG 0903","volume":"34","author":"Mileshkin","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1200\/JCO.2014.58.3401","article-title":"Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma","volume":"33","author":"Slomovitz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1634\/theoncologist.2016-0062","article-title":"Chemotherapy for endometrial cancer in adjuvant and advanced disease settings","volume":"21","author":"Bestvina","year":"2016","journal-title":"Oncologist"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1525-1438.2007.01094.x","article-title":"Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel: Long-term follow-up","volume":"18","author":"Sorbe","year":"2008","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ygyno.2013.09.021","article-title":"Applicability of the concept of \u201cplatinum sensitivity\u201d to recurrent endometrial cancer: The SGSG-012\/GOTIC-004\/Intergroup study","volume":"131","author":"Nagao","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0090-8258(02)00068-9","article-title":"Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: A Gynecologic Oncology Group study","volume":"88","author":"Lincoln","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1200\/JCO.2017.72.5952","article-title":"Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: Results from the KEYNOTE-028 study","volume":"35","author":"Ott","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T-cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00262-014-1537-8","article-title":"Mapping the immunosuppressive environment in uterine tumors: Implications for immunotherapy","volume":"63","author":"Vanderstraeten","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: Results from the KEYNOTE-158 study","volume":"40","author":"Bariani","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.ygyno.2019.06.016","article-title":"Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy","volume":"154","author":"Prendergast","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/sj.bjc.6603012","article-title":"Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers","volume":"94","author":"Hamilton","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"36652","DOI":"10.18632\/oncotarget.26413","article-title":"Targeting Her2\/neu in uterine serous carcinoma: A paradigm shift in management","volume":"9","author":"Lopez","year":"2018","journal-title":"Oncotarget"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/9\/574\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:40:12Z","timestamp":1760128812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/9\/574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,27]]},"references-count":110,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["curroncol30090574"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30090574","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,27]]}}}